Curaleaf HoldingsCURLD -1.48%67 PB Ratio is 2.96 as of Jun. 25, 2026, which is 7% below its 10-year median of 3.19. GuruFocus rates CURLD with a GF Score™ of 67/100 and a GF Value™ of $8.11 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 69.2% on this metric.
The historical rank and industry rank for Curaleaf Holdings's PB Ratio or its related term are showing as below:
CURLD'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 3.19 Max: 39.2
Current: 3
During the past 12 years, Curaleaf Holdings's highest PB Ratio was 39.20. The lowest was 0.01. And the median was 3.19.
CURLD's PB Ratio is ranked worse than 69.2% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs CURLD: 3.00
During the past 12 months, Curaleaf Holdings's average Book Value Per Share Growth Rate was -6.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -17.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.60% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Curaleaf Holdings was 1063.10% per year. The lowest was -71.60% per year. And the median was 28.40% per year.
Back to Basics: PB Ratio
Curaleaf Holdings (OTCPK:CURLD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Curaleaf Holdings PB Ratio Related Terms
Curaleaf Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Curaleaf Holdings (CURLD) has a PB Ratio of 2.96 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Curaleaf Holdings and its competitors. This is near median its historical median of 3.19. Over the past decade, Curaleaf Holdings' PB Ratio has ranged from 0.01 to 39.20. According to the industry distribution chart, Curaleaf Holdings ranks #638 out of 922 companies in the Drug Manufacturers industry, placing it in the top 69.2%.
Is Curaleaf Holdings' PB Ratio too high?
Curaleaf Holdings' current PB Ratio of 2.96 is near median its 10-year median of 3.19. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 39.20. The Drug Manufacturers industry median PB Ratio is 1.88. Curaleaf Holdings' value of 2.96 is 57.4% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #638 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #638 out of 922 companies for PB Ratio. This places Curaleaf Holdings in the lower half of its industry. The industry median PB Ratio is 1.88. Curaleaf Holdings' value of 2.96 is 57.4% above this benchmark. Historically, Curaleaf Holdings' own PB Ratio has ranged from 0.01 to 39.20 over the past decade. While the company's 10-year median is 3.19 vs. the industry median of 1.88, Curaleaf Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current PB Ratio of 2.96 is 57.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current PB Ratio is 2.96, which is near median its own 10-year median of 3.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLD) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.11, compared to a current price of $9.33 — trading 15% above its estimated fair value. The current PB Ratio is 2.96, which is near median its 10-year median of 3.19 and 57.4% above the Drug Manufacturers industry median of 1.88. Curaleaf Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Curaleaf Holdings (CURLD), the current PB Ratio is 2.96 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLD) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.33 is trading 15% above its estimated GF Value™ of $8.11.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLD:
PB Ratio: 2.96 (near median its 10-year median of 3.19)
GF Value™: $8.11 vs. price of $9.33 (15% above fair value)
Industry Position: 57.4% above the Drug Manufacturers median (#638 of 922)
No single metric tells the full story. See the CURLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
67GF Score
Get the complete analysis for CURLD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLD has been successfully added to your 
